BRPI0418093A - vìrion de um pneumovìrus, método para produzir vìrions pneumovirais, composição, uso de um vìrion, e, método para a prevenção ou tratamento de uma infecção pneumoviral - Google Patents

vìrion de um pneumovìrus, método para produzir vìrions pneumovirais, composição, uso de um vìrion, e, método para a prevenção ou tratamento de uma infecção pneumoviral

Info

Publication number
BRPI0418093A
BRPI0418093A BRPI0418093-3A BRPI0418093A BRPI0418093A BR PI0418093 A BRPI0418093 A BR PI0418093A BR PI0418093 A BRPI0418093 A BR PI0418093A BR PI0418093 A BRPI0418093 A BR PI0418093A
Authority
BR
Brazil
Prior art keywords
virion
pneumoviral
virions
pneumovirus
producing
Prior art date
Application number
BRPI0418093-3A
Other languages
English (en)
Inventor
Willem Luytjes
Myra Noorely Widjojoatmodjo
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Publication of BRPI0418093A publication Critical patent/BRPI0418093A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18532—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material
    • C12N2760/18552—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"VìRION DE UM PNEUMOVìRUS, MéTODO PARA PRODUZIR VìRIONS PNEUMOVIRAIS, COMPOSIçãO, USO DE UM VìRION, E, MéTODO PARA A PREVENçãO OU TRATAMENTO DE UMA INFECçãO PNEUMOVIRAL". A presente invenção refere-se a vírions pneumovirais compreendendo um genoma viral que tem uma mutação em um gene codificando para uma proteína que e essencial para infecciosidade do pneumovírus, assim a mutação leva um vírus produzido a partir de somente o genoma viral a faltar infecciosidade, e assim o vírion compreende a proteína em uma forma e em uma quantidade que é requerida para infecciosidade do vírion. A invenção refere-se a métodos para produzir os vírions pneumovirais e para usar os vírions no tratamento ou prevenção de infecção e doença pneumoviral. Um vírion pneumoviral preferido é um vírion do vírus sincicial respiratório em que preferivelmente o gene para a proteína de fixação G é inativada e complementada em trans.
BRPI0418093-3A 2003-12-24 2004-12-24 vìrion de um pneumovìrus, método para produzir vìrions pneumovirais, composição, uso de um vìrion, e, método para a prevenção ou tratamento de uma infecção pneumoviral BRPI0418093A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL0300930 2003-12-24
PCT/NL2004/000911 WO2005061698A1 (en) 2003-12-24 2004-12-24 A respiratory syncytial virus with a genomic deficiency complemented in trans

Publications (1)

Publication Number Publication Date
BRPI0418093A true BRPI0418093A (pt) 2007-04-17

Family

ID=34709376

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418093-3A BRPI0418093A (pt) 2003-12-24 2004-12-24 vìrion de um pneumovìrus, método para produzir vìrions pneumovirais, composição, uso de um vìrion, e, método para a prevenção ou tratamento de uma infecção pneumoviral

Country Status (24)

Country Link
US (3) US9107939B2 (pt)
EP (2) EP2500419B1 (pt)
JP (1) JP4814799B2 (pt)
KR (1) KR101266715B1 (pt)
CN (1) CN1922309B (pt)
AU (1) AU2004303719B2 (pt)
BR (1) BRPI0418093A (pt)
CA (1) CA2551009C (pt)
CY (1) CY1118741T1 (pt)
DK (1) DK1699919T3 (pt)
EA (1) EA011878B1 (pt)
ES (2) ES2618523T3 (pt)
HK (1) HK1100494A1 (pt)
HU (1) HUE032898T2 (pt)
IL (1) IL176500A (pt)
LT (1) LT1699919T (pt)
NO (1) NO334756B1 (pt)
NZ (1) NZ548107A (pt)
PL (1) PL1699919T3 (pt)
PT (1) PT1699919T (pt)
SI (1) SI1699919T1 (pt)
TR (1) TR201808496T4 (pt)
WO (1) WO2005061698A1 (pt)
ZA (1) ZA200605218B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121210D0 (en) * 2011-12-09 2012-01-18 Health Prot Agency Respiratory infection assay
KR102108876B1 (ko) 2012-03-05 2020-05-12 드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 베이웨이에스, 미니스테리 반 폭스겐트존하이트, 벨지인 엔 스포츠 건조된 생물학적 물질을 안정화시키는 방법 및 조성물
JP6506249B2 (ja) 2013-03-14 2019-04-24 エモリー ユニバーシティー サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
BR112015031541A2 (pt) 2013-06-17 2017-07-25 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport métodos para o impedimento da agregação de componentes virais
EP3888676A1 (en) 2014-06-13 2021-10-06 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
WO2017075125A1 (en) 2015-10-29 2017-05-04 Emory University Chimeric RSV, Immunogenic Compositions, and Methods of Use
US10626126B2 (en) * 2016-04-08 2020-04-21 Pulmocide Limited Compounds
CN112746059A (zh) * 2020-09-15 2021-05-04 清华大学 基于病毒结构蛋白遗传互补的冠状病毒细胞模型
CN112501134B (zh) * 2020-12-09 2023-01-20 贵州医科大学附属医院 一种人呼吸道合胞病毒毒株及其应用
CN114990079B (zh) * 2022-04-29 2023-07-04 广州医科大学附属第一医院（广州呼吸中心） 治疗性缺陷干扰颗粒及其在制备用于防治rsv病毒感染的产品中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69532369T3 (de) * 1994-07-18 2010-11-04 Conzelmann, Karl-Klaus, Prof. Dr. Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
US5789229A (en) 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US6264957B1 (en) * 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
WO1998002530A1 (en) 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
EP1035205A1 (en) 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
US6921535B2 (en) * 2000-06-23 2005-07-26 Akzo Nobel N.V. Attenuated Bovine Respiratory Syncytial virus
AU2002343462A1 (en) * 2001-10-01 2003-04-14 Uab Research Foundation Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof

Also Published As

Publication number Publication date
US20180207211A1 (en) 2018-07-26
EP1699919B1 (en) 2017-01-11
CA2551009A1 (en) 2005-07-07
SI1699919T1 (sl) 2017-07-31
US20100291035A1 (en) 2010-11-18
CY1118741T1 (el) 2017-07-12
ZA200605218B (en) 2007-05-30
US9889168B2 (en) 2018-02-13
CN1922309B (zh) 2011-07-13
NZ548107A (en) 2009-09-25
PL1699919T3 (pl) 2017-08-31
EP1699919A1 (en) 2006-09-13
CA2551009C (en) 2017-01-17
ES2670713T3 (es) 2018-05-31
IL176500A0 (en) 2006-10-05
ES2618523T3 (es) 2017-06-21
EP2500419B1 (en) 2018-03-21
EA011878B1 (ru) 2009-06-30
LT1699919T (lt) 2017-04-25
HUE032898T2 (hu) 2017-11-28
IL176500A (en) 2015-02-26
US10967014B2 (en) 2021-04-06
TR201808496T4 (tr) 2018-07-23
EA200601218A1 (ru) 2006-12-29
AU2004303719B2 (en) 2010-11-11
DK1699919T3 (en) 2017-03-20
US20150329833A1 (en) 2015-11-19
US9107939B2 (en) 2015-08-18
AU2004303719A1 (en) 2005-07-07
KR101266715B1 (ko) 2013-05-28
KR20070022210A (ko) 2007-02-26
EP2500419A1 (en) 2012-09-19
WO2005061698A1 (en) 2005-07-07
PT1699919T (pt) 2017-04-03
HK1100494A1 (en) 2007-09-21
NO20062967L (no) 2006-09-22
CN1922309A (zh) 2007-02-28
JP4814799B2 (ja) 2011-11-16
NO334756B1 (no) 2014-05-19
JP2007516721A (ja) 2007-06-28

Similar Documents

Publication Publication Date Title
TW200733953A (en) Materials and methods for treating viral infections
BR0308444A (pt) Composição de vacina, método de produção de vacina, uso de uma mistura de vlps de hpv 16, hpv 18, hvp 31 e hpv 45, método de prevenção da infecção por hpv ou tratamento de doença relacionada com a infecção por hpv
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
BRPI0416187A (pt) método de prevenir fusão de vìrus: célula inibindo a função da região de iniciação de fusão em vìrus de rna tendo proteìnas de envelope fusogênico de membrana da classe i
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
BRPI0418093A (pt) vìrion de um pneumovìrus, método para produzir vìrions pneumovirais, composição, uso de um vìrion, e, método para a prevenção ou tratamento de uma infecção pneumoviral
BR0207752A (pt) Composto, sais de sódio, cálcio, potássio, magnésio, colina, etanolamina e trietilamina dos compostos, formas dos mesmos, métodos de tratamento ou de prevenção de uma infeção viral em um ser humano e de tratamento dos vìrus mutantes hiv uso de um composto, composição farmacêutica, e, processo para a preparação dos compostos
DE122011100037I1 (de) Rekombinante influenzaviren zur vakzinherstellung und gentherapie.
ATE547118T1 (de) Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung
DE602006014720D1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
WO2022010938A3 (en) Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
WO2001097824A3 (de) Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch flaviviridae
JP2003528925A5 (pt)
WO2009023356A3 (en) Materials and methods for treating influenza infections
ATE493408T1 (de) Antiinfektiöse mittel
ATE295159T1 (de) Bupropion zur behandlung von viralen erkrankungen
KR970701561A (ko) 신규 기도부 바이러스 질환 치료제(Novel Remedy for Respiratory-Tract Viral Disease)
BR0101523A (pt) Pestivìrus, vacina, e, processos para imunizarcontra doença induzida por pestivìrus e parafabricar uma vacina para a proteção de um animalcontra um pestivìrus
BRPI0401466A (pt) Composição para inativação viral, processo de inativação viral, vacina e processo de produção de vacina
TH97642A (th) วัสดุ และวิธีการสำหรับการรักษาการติดเชื้อไวรัส
TH97642B (th) วัสดุ และวิธีการสำหรับการรักษาการติดเชื้อไวรัส
UY26563A1 (es) Atenuación recombinante de prrsv
ATE266403T1 (de) Verwendung von 2-methyl-thiazolidin 2,4- dicarbonsäure zur herstellung eines medikaments zur behandlung von infektionskrankheiten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL